Why the study?
Does contemporary combined immunosuppression improve clinical remission in patients with giant-cell myocarditis?
Does contemporary combined immunosuppression improve clinical remission in patients with giant-cell myocarditis?
Combined immunosuppression allows most giant-cell myocarditis patients to avoid severe heart failure and transplantation, though ventricular arrhythmia risk persists.
Answers are grounded in this paper and cite their sources.
Contemporary immunosuppression may enable transplantation-free remission in giant-cell myocarditis; leaves open arrhythmia-specific risk reduction strategies.
Repeat endomyocardial biopsies are frequently needed to diagnose giant-cell myocarditis. On contemporary immunosuppession, two thirds of patients reach a partial clinical remission characterized by freedom from severe heart failure and need of transplantation but continuing proneness to ventricular tachyarrhythmias.
No takes yet. Share an insight, caveat, or question.
Kandolin et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: